Association of patient profile with glycemic control and hypoglycemia with insulin glargine 300 U/mL in type 2 diabetes: A post hoc patient-level meta-analysis

Aims To examine the association of baseline patient characteristics with study outcomes in people with type 2 diabetes receiving insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100), over a 6-month period. Methods A post hoc patient-level meta-analysis using data from three multice...

Descripción completa

Detalles Bibliográficos
Autores: Twigg, S.M. (Stephen M.)|||/items/1903914b-2bc7-4b67-8131-b82598c0a56a, Escalada, J. (Javier)|||/items/49a6b2d2-0f66-4005-b584-099f1728e80b, Stella, P. (Peter)|||/items/fd556e60-c3cb-49dc-ae6a-6edc6b747b8c, Merino-Trigo, A. (A.)|||/items/f64fec40-6530-4468-ab0d-a2c0d4e8ed79, Lavalle-Gonzalez, F.J. (Fernando J.)|||/items/c2e9be50-0584-41a5-a499-5b094d6bd9e0, Cariou, B. (Bertrand)|||/items/05e7d865-fe53-4264-9652-1869fcf6292a, Meneghini, L.F. (Luigi F.)|||/items/78c73a49-9f62-46ac-9feb-54133a9d8ff1
Tipo de recurso: artículo
Fecha de publicación:2018
País:España
Institución:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/65817
Acceso en línea:https://hdl.handle.net/10171/65817
Access Level:acceso abierto
Palabra clave:Glycated hemoglobin A
Hypoglycemia
Insulin glargine
Type 2 diabetes
id ES_33c2cbae788b17cdef5ab79ccbfa3d1a
oai_identifier_str oai:dadun.unav.edu:10171/65817
network_acronym_str ES
network_name_str España
repository_id_str
spelling Association of patient profile with glycemic control and hypoglycemia with insulin glargine 300 U/mL in type 2 diabetes: A post hoc patient-level meta-analysisTwigg, S.M. (Stephen M.)|||/items/1903914b-2bc7-4b67-8131-b82598c0a56aEscalada, J. (Javier)|||/items/49a6b2d2-0f66-4005-b584-099f1728e80bStella, P. (Peter)|||/items/fd556e60-c3cb-49dc-ae6a-6edc6b747b8cMerino-Trigo, A. (A.)|||/items/f64fec40-6530-4468-ab0d-a2c0d4e8ed79Lavalle-Gonzalez, F.J. (Fernando J.)|||/items/c2e9be50-0584-41a5-a499-5b094d6bd9e0Cariou, B. (Bertrand)|||/items/05e7d865-fe53-4264-9652-1869fcf6292aMeneghini, L.F. (Luigi F.)|||/items/78c73a49-9f62-46ac-9feb-54133a9d8ff1Glycated hemoglobin AHypoglycemiaInsulin glargineType 2 diabetesAims To examine the association of baseline patient characteristics with study outcomes in people with type 2 diabetes receiving insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100), over a 6-month period. Methods A post hoc patient-level meta-analysis using data from three multicenter, randomized, open-label, parallel-group, phase 3a studies of similar design, in people previously receiving either basal and prandial insulin, basal insulin + oral antihyperglycemic drugs, or no prior insulin (EDITION 1, 2 and 3, respectively). The endpoints, glycated hemoglobin (HbA1c), hypoglycemia, body weight change, and insulin dose were investigated by subgroups: age (< 65 and ≥ 65 years), body mass index (BMI; < 30 and ≥ 30 kg/m2), age at onset (< 40, 40–50, and > 50 years), and diabetes duration (< 10 and ≥ 10 years). Results Reduction in HbA1c was comparable between insulins, regardless of subgroup. The lower risk of ≥ 1 nocturnal (00:00–05:59 h) confirmed (≤ 3.9 mmol/L [≤ 70 mg/dL]) or severe hypoglycemic event with Gla-300 versus Gla-100 was also unaffected by participant characteristics. While heterogeneity of treatment effect between diabetes duration subgroups was seen for the risk of ≥ 1 confirmed (≤ 3.9 mmol/L [≤ 70 mg/dL]) or severe hypoglycemic event at any time (24 h), treatment effect consistently favored Gla-300; no evidence of heterogeneity was observed for the other subgroups. Annualized rates of confirmed (≤ 3.9 mmol/L [≤ 70 mg/dL]) or severe hypoglycemia and body weight change were not influenced by participant characteristics; a similar pattern was observed with insulin dose. Conclusions Comparable glycemic control was observed with Gla-300 versus Gla-100, with less hypoglycemia, regardless of age, BMI, age at onset or diabetes duration.SpringerDadun. Depósito Académico Digital Universidad de Navarra20232023-03-3020182018-01-0120182018-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/65817reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/658172026-06-21T12:47:57Z
dc.title.none.fl_str_mv Association of patient profile with glycemic control and hypoglycemia with insulin glargine 300 U/mL in type 2 diabetes: A post hoc patient-level meta-analysis
title Association of patient profile with glycemic control and hypoglycemia with insulin glargine 300 U/mL in type 2 diabetes: A post hoc patient-level meta-analysis
spellingShingle Association of patient profile with glycemic control and hypoglycemia with insulin glargine 300 U/mL in type 2 diabetes: A post hoc patient-level meta-analysis
Twigg, S.M. (Stephen M.)|||/items/1903914b-2bc7-4b67-8131-b82598c0a56a
Glycated hemoglobin A
Hypoglycemia
Insulin glargine
Type 2 diabetes
title_short Association of patient profile with glycemic control and hypoglycemia with insulin glargine 300 U/mL in type 2 diabetes: A post hoc patient-level meta-analysis
title_full Association of patient profile with glycemic control and hypoglycemia with insulin glargine 300 U/mL in type 2 diabetes: A post hoc patient-level meta-analysis
title_fullStr Association of patient profile with glycemic control and hypoglycemia with insulin glargine 300 U/mL in type 2 diabetes: A post hoc patient-level meta-analysis
title_full_unstemmed Association of patient profile with glycemic control and hypoglycemia with insulin glargine 300 U/mL in type 2 diabetes: A post hoc patient-level meta-analysis
title_sort Association of patient profile with glycemic control and hypoglycemia with insulin glargine 300 U/mL in type 2 diabetes: A post hoc patient-level meta-analysis
dc.creator.none.fl_str_mv Twigg, S.M. (Stephen M.)|||/items/1903914b-2bc7-4b67-8131-b82598c0a56a
Escalada, J. (Javier)|||/items/49a6b2d2-0f66-4005-b584-099f1728e80b
Stella, P. (Peter)|||/items/fd556e60-c3cb-49dc-ae6a-6edc6b747b8c
Merino-Trigo, A. (A.)|||/items/f64fec40-6530-4468-ab0d-a2c0d4e8ed79
Lavalle-Gonzalez, F.J. (Fernando J.)|||/items/c2e9be50-0584-41a5-a499-5b094d6bd9e0
Cariou, B. (Bertrand)|||/items/05e7d865-fe53-4264-9652-1869fcf6292a
Meneghini, L.F. (Luigi F.)|||/items/78c73a49-9f62-46ac-9feb-54133a9d8ff1
author Twigg, S.M. (Stephen M.)|||/items/1903914b-2bc7-4b67-8131-b82598c0a56a
author_facet Twigg, S.M. (Stephen M.)|||/items/1903914b-2bc7-4b67-8131-b82598c0a56a
Escalada, J. (Javier)|||/items/49a6b2d2-0f66-4005-b584-099f1728e80b
Stella, P. (Peter)|||/items/fd556e60-c3cb-49dc-ae6a-6edc6b747b8c
Merino-Trigo, A. (A.)|||/items/f64fec40-6530-4468-ab0d-a2c0d4e8ed79
Lavalle-Gonzalez, F.J. (Fernando J.)|||/items/c2e9be50-0584-41a5-a499-5b094d6bd9e0
Cariou, B. (Bertrand)|||/items/05e7d865-fe53-4264-9652-1869fcf6292a
Meneghini, L.F. (Luigi F.)|||/items/78c73a49-9f62-46ac-9feb-54133a9d8ff1
author_role author
author2 Escalada, J. (Javier)|||/items/49a6b2d2-0f66-4005-b584-099f1728e80b
Stella, P. (Peter)|||/items/fd556e60-c3cb-49dc-ae6a-6edc6b747b8c
Merino-Trigo, A. (A.)|||/items/f64fec40-6530-4468-ab0d-a2c0d4e8ed79
Lavalle-Gonzalez, F.J. (Fernando J.)|||/items/c2e9be50-0584-41a5-a499-5b094d6bd9e0
Cariou, B. (Bertrand)|||/items/05e7d865-fe53-4264-9652-1869fcf6292a
Meneghini, L.F. (Luigi F.)|||/items/78c73a49-9f62-46ac-9feb-54133a9d8ff1
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Dadun. Depósito Académico Digital Universidad de Navarra
dc.subject.none.fl_str_mv Glycated hemoglobin A
Hypoglycemia
Insulin glargine
Type 2 diabetes
topic Glycated hemoglobin A
Hypoglycemia
Insulin glargine
Type 2 diabetes
description Aims To examine the association of baseline patient characteristics with study outcomes in people with type 2 diabetes receiving insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100), over a 6-month period. Methods A post hoc patient-level meta-analysis using data from three multicenter, randomized, open-label, parallel-group, phase 3a studies of similar design, in people previously receiving either basal and prandial insulin, basal insulin + oral antihyperglycemic drugs, or no prior insulin (EDITION 1, 2 and 3, respectively). The endpoints, glycated hemoglobin (HbA1c), hypoglycemia, body weight change, and insulin dose were investigated by subgroups: age (< 65 and ≥ 65 years), body mass index (BMI; < 30 and ≥ 30 kg/m2), age at onset (< 40, 40–50, and > 50 years), and diabetes duration (< 10 and ≥ 10 years). Results Reduction in HbA1c was comparable between insulins, regardless of subgroup. The lower risk of ≥ 1 nocturnal (00:00–05:59 h) confirmed (≤ 3.9 mmol/L [≤ 70 mg/dL]) or severe hypoglycemic event with Gla-300 versus Gla-100 was also unaffected by participant characteristics. While heterogeneity of treatment effect between diabetes duration subgroups was seen for the risk of ≥ 1 confirmed (≤ 3.9 mmol/L [≤ 70 mg/dL]) or severe hypoglycemic event at any time (24 h), treatment effect consistently favored Gla-300; no evidence of heterogeneity was observed for the other subgroups. Annualized rates of confirmed (≤ 3.9 mmol/L [≤ 70 mg/dL]) or severe hypoglycemia and body weight change were not influenced by participant characteristics; a similar pattern was observed with insulin dose. Conclusions Comparable glycemic control was observed with Gla-300 versus Gla-100, with less hypoglycemia, regardless of age, BMI, age at onset or diabetes duration.
publishDate 2018
dc.date.none.fl_str_mv 2018
2018-01-01
2018
2018-01-01
2023
2023-03-30
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10171/65817
url https://hdl.handle.net/10171/65817
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra
instname:Universidad de Navarra
instname_str Universidad de Navarra
reponame_str Dadun. Depósito Académico Digital de la Universidad de Navarra
collection Dadun. Depósito Académico Digital de la Universidad de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869405767375781889
score 15,300719

Similares en LA Referencia